Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750643 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT03750643 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 128 participants.
The verdict
NCT03750643, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.
Interventions
- DRUG Placebo
- DRUG LY3454738
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03750643
The ClinicalTrials.gov registry entry for NCT03750643 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03750643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03750643 about?
NCT03750643 is a clinical study titled "A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis". The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depen...
What is the current status of trial NCT03750643?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2018-11-29. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT03750643?
The interventions under investigation include: Placebo (DRUG), LY3454738 (DRUG).
Who is sponsoring clinical trial NCT03750643?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.